Investigator Initiated Study (IIS) Artifacts

An Investigator Initiated Study (IIS)also referred to as an Investigator Sponsored Study (ISS)is a clinical trial where an individual investigator, rather than a pharmaceutical or device company, takes the role of the sponsor. In this model, the investigator assumes full responsibility for the initiation, management, and financing of the clinical research. Consequently, the investigator is also responsible for maintaining a robust collection of study artifacts.

Study artifacts are the essential documents and records that provide evidence of the trial's conduct, integrity, and compliance with Good Clinical Practice (GCP) guidelines. Managing these artifacts is critical for ensuring the safety of participants and the validity of the data collected.

Key Categories of IIS Artifacts

IIS artifacts are generally categorized based on the stage of the study. A well-organized Trial Master File (TMF) contains these documents, which are grouped as follows:

• Regulatory and Administrative Documents: This includes the study protocol, investigators brochure, curriculum vitae for all study staff, documentation of financial disclosures, and the initial approval from the Institutional Review Board (IRB) or Ethics Committee (EC).
• Site-Specific Documentation: These artifacts include site initiation visit reports, delegation of authority logs, staff training records, and evidence of local facility certifications or laboratory accreditations.
• Informed Consent Records: Arguably the most critical set of artifacts, these consist of the IRB-approved Informed Consent Forms (ICF), templates, and signed versions from every participant, ensuring ethical standards are met.
• Clinical Data Records: These include Case Report Forms (CRFs), source documentation, medical histories, lab reports, and medication logs that justify the data entries made in the study database.
• Safety and Pharmacovigilance Records: Documentation regarding Adverse Events (AEs) and Serious Adverse Events (SAEs). This includes reports submitted to the IRB, regulatory authorities, and, if applicable, the commercial entity providing the study drug or device.
• Study Correspondence: A chronological trail of communications between the investigator, the site staff, the IRB/EC, and any regulatory bodies. This also includes documentation of any monitoring visits or audits.

The Importance of Version Control

In an IIS, the investigator is responsible for maintaining the most current versions of all documents. When a protocol is amended or an ICF is revised, the investigator must ensure that old versions are archived and clearly marked as superseded, while the new versions are implemented and distributed to relevant staff. Failure to maintain clear version control can lead to non-compliance, which may invalidate study results or cause regulatory sanctions.

Audit Readiness

Since the investigator acts as the sponsor in an IIS, they are often subject to direct inspections by regulatory bodies such as the FDA or EMA. Maintaining "audit readiness" is a fundamental pillar of IIS management. This means that artifacts should be organized in such a way that an external auditor could reconstruct the history of the trial from start to finish. Essential elements for audit readiness include:

• Consistent naming conventions for electronic files.
• Periodic quality checks to ensure all signatures and dates are present and legible.
• Secure storage of physical documents and validated backup processes for electronic data.
• Clearly defined standard operating procedures (SOPs) that dictate how artifacts are collected, filed, and retained.

Data Integrity and Retention

Beyond the conclusion of the study, the investigator must manage the retention of artifacts. Regulations typically dictate a specific period (often several years after the study is completed or after the drug is approved) during which these artifacts must be preserved. Investigators must ensure that storage environmentswhether digital or physicalare protected against unauthorized access, destruction, or environmental damage, such as humidity or fire.

Conclusion

The successful execution of an Investigator Initiated Study relies heavily on the meticulous management of study artifacts. By viewing the collection and maintenance of these documents not as a bureaucratic burden, but as the fundamental evidence of research excellence, investigators can ensure the safety of their participants and the credibility of their scientific contributions.